Safety, Efficacy, and Quality of Life Outcomes of Subcutaneous Lonigutamab (Anti-IGF-1R): Week 12 Results From a Phase 1/2 Proof of Concept Study in Patients With Thyroid Eye Disease (TED)

Authors

Shoaib Ugradar
David A. Kostick
Jane Spadaro, Corewell Health East
Dinesh Selva
Jean-Louis deSousa
Krishna Tumuluri
Jwu Jin Khong

Document Type

Conference Proceeding

Publication Date

10-16-2025

First Page

20

Comments

American Society of Ophthalmic Plastic and Reconstructive Surgery 56th Annual Fall Scientific Symposium, October 16-17, 2025, Orlando, FL

Last Page

20

Recommended Citation

Ugradar S, Kostick DA, Spadaro J, Selva D, deSousa JL, Tumuluri K, et al. Safety, efficacy, and quality of life outcomes of subcutaneous lonigutamab (anti-IGF-1R): week 12 results from a phase 1/2 proof of concept study in patients with thyroid eye disease (TED). Presented at: American Society of Ophthalmic Plastic and Reconstructive Surgery 56th Annual Fall Scientific Symposium; 2025 Oct 16; Orlando, FL. Available from:https://asoprs.memberclicks.net/assets/Meetings/fall/ASOPRS_2025_Fall_Program.pdf